Articles

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Pivotal subretinal gene therapy trial begins

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Patient with retinitis pigmentosa achieves partial vision through gene therapy

Preexisting neutralizing antibodies associated with the inflammatory changes.

Investigating inflammation caused by intravitreal brolucizumab

Novel therapies are shifting the paradigm in care of retinal diseases 

The posterior segment: In search of topical treatment options

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

The eye may be a point of SARS-CoV-2 infection, study suggests

Study results show that aflibercept-treated eyes are protected.

Retinal leakage and nonperfusion linked with center-involved DME

Study results show the device offers an effective long-term option for patients.

Treating chronic uveitis with fluocinolone acetonide implants

Retinal imaging tests are providing material to train and test decision support systems.

How ophthalmology is pioneering the field of artificial intelligence 

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment

Members of the medical community gather virtually to discuss current issues in the field, public health, and general business.

How ophthalmology is pioneering the field of artificial intelligence

Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment

AMA calls virtual special meeting, gathering June 11